Opicapone for the treatment of Parkinson’s disease: an update

András Salamon, Dénes Zádori, László Szpisjak, Péter Klivényi, László Vécsei

Research output: Contribution to journalArticle

1 Citation (Scopus)


Introduction: Parkinson’s disease is a neurodegenerative disorder which is characterized by the combination of motor and non-motor symptoms. As yet, there is no curative treatment. The gold standard for symptom control is levodopa. Two years after the start of substitution therapy, around 50% of patients experience some degree of fluctuation in motor performance. Catechol-O-methyltransferase (COMT) inhibitors are important agents in treating these fluctuations. Areas covered: This article summarizes our knowledge about a new third-generation COMT inhibitor, namely opicapone (OPC) (Search period: 2016–2019). The authors detail the pharmacological profile of OPC and summarize the results of completed clinical trials. In addition, they briefly summarize the achievements of the past few years. Expert opinion: Based on clinical trials conducted so far, OPC is an effective and safe new drug. In comparison to entacapone and tolcapone, it does not require close laboratory monitoring or multiple oral administrations, which may result in better adherence. No serious adverse event was reported during the drug development phases. Dyskinesia was the most common complaint. Further comparative studies and broader trial inclusion criteria are needed to help the decision between COMT inhibitors and to expand the patient spectrum where this drug can be applied.

Original languageEnglish
Pages (from-to)2201-2207
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number18
Publication statusPublished - Dec 12 2019


  • COMT inhibitor
  • Parkinson’s disease
  • opicapone

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Opicapone for the treatment of Parkinson’s disease: an update'. Together they form a unique fingerprint.

  • Cite this